Effect of carvedilol on silent anthracycline-induced cardiotoxicity assessed by strain imaging: A prospective randomized controlled study with six-month follow-up

Cardiology Journal

Volumn 21, Issue 5, 2014, Pages 509-515

  Elitok, Ali ^a   Oz, Fahrettin ^a   Ahmet, Y ^a   Kilic, Leyla ^a   Ciftci, Rumeysa ^a   Sen, Fatma ^a   Bugra, Zehra ^a   Mercanoglu, Fehmi ^a   Oncul, Aytac ^a   Oflaz, Huseyin ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Antracycline induced cardiotoxicity; Beta Blocker; Carvedilol; Echocardiography; Strain imaging

Indexed keywords

ANTHRACYCLINE; CARVEDILOL; HEMOGLOBIN; PLACEBO; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAZOLE DERIVATIVE; PROPANOLAMINE DERIVATIVE;

ADULT; ANTHRACYCLINE INDUCED CARDIOTOXICITY; ARTICLE; BREAST CANCER; CARDIOTOXICITY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; FEMALE; FOLLOW UP; FRACTIONAL SHORTENING; HEART LEFT ATRIUM; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART LEFT VENTRICLE FUNCTION; HEART PROTECTION; HEART VENTRICLE SEPTUM; HUMAN; M MODE ECHOCARDIOGRAPHY; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STRAIN IMAGING; SYSTOLIC BLOOD PRESSURE; TISSUE DOPPLER IMAGING; TWO DIMENSIONAL ECHOCARDIOGRAPHY; BREAST NEOPLASMS; CHEMICALLY INDUCED; DOPPLER ECHOCARDIOGRAPHY; DOSE RESPONSE; DRUG EFFECTS; ECHOGRAPHY; HEART STROKE VOLUME; HEART VENTRICLE; MIDDLE AGED; PATHOPHYSIOLOGY; PROCEDURES; TIME; TREATMENT OUTCOME;

ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; ANTHRACYCLINES; BREAST NEOPLASMS; CARBAZOLES; DOSE-RESPONSE RELATIONSHIP, DRUG; ECHOCARDIOGRAPHY, DOPPLER, PULSED; FEMALE; FOLLOW-UP STUDIES; HEART VENTRICLES; HUMANS; MIDDLE AGED; PROPANOLAMINES; PROSPECTIVE STUDIES; STROKE VOLUME; TIME FACTORS; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84908301110     PISSN: 18975593     EISSN: 1898018X     Source Type: Journal    
DOI: 10.5603/CJ.a2013.0150     Document Type: Article

References (31)

1. WHO Disease and injury country estimates. World Health Organization. 2009. Retrieved Nov. 11, 2009
2. Mornoş C, Petrescu L. Early detection of anthracycline-mediated cardiotoxicity: the value of considering both global longitudinal left ventricular strain and twist. Can J Physiol Pharmacol, 2013; 91: 601–607
3. Von Hoff DD, Layard MW, Basa P et al. Risk factors for doxorubicin--induced congestive heart failure. Ann Intern Med, 1979; 91: 710–717
4. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials. Cancer, 2003; 97: 2869–2879
5. Heimdal A, Stoylen A, Torp H et al. Real-time strain rate imaging of the left ventricle by ultrasound. J Am Soc Echocardio, 1998; 11: 1013–1019
6. Singal PK, Li T, Kumar D, Danelisen I, Iliskovic N. Adriamycin- induced heart failure: mechanism and modulation. Mol Cell Biochem, 2000; 207: 77–86
7. Dulin B, Abraham WT. Pharmacology of carvedilol. Am J Cardiol, 200; 93: 3B–6B
8. Kalay N, Basar E, Ozdogru I et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol, 2006; 48: 2258–2262
9. Sahn DJ, DeMaria A, Kisslo J et al. Recommendations regarding quantitation in M-mode echocardiography: Results of a survey of echocardiographic measurements. Circulation, 1978; 58: 1072–1083
10. Steinherz LJ, Graham T, Hurwitz R et al. Guidelines for monitoring of anthracycline cardiomyopathy: A rebuttal. Pediatrics, 1994; 94: 782–784
11. D’Andrea A, Stisi S, Bellissimo S et al. Early impairment of myocardialfunction in systemic sclerosis:non-invasiveassessment by Doppler myocardial and strain rate imaging. Eur J Echocardiogr, 2005; 6: 407–418
12. Hamdy AM. Use of strain and tissue velocity imaging for early detection of regional myocardial dysfunction in patients with beta thalassemia. Eur J Echocardiogr, 2007; 8: 102–109
13. Jurcut R, Wildiers H, Ganame J et al. Strain rate imaging detects early cardiac effects of pegylated liposomal doxorubicin as adjuvant therapy in elderly patients with breast cancer. J Am Soc Echocardiogr, 2008; 21: 1283–1289
14. Cheung YF, Hong WJ, Chan GC, Wong SJ, Ha SY. Left ventricular myocardial deformation and mechanical dyssynchrony in children with normal ventricular shortening fraction after anthracycline therapy. Heart, 2010; 96: 1137–1141
15. Stoodley PW, Richards DA, Hui R et al. Two-dimensional myocardial strain imaging detects changes in left ventricular systolic function immediately after anthracycline chemotherapy. Eur J Echocardiogr, 2011; 12: 945–952
16. Sawaya H, Sebag IA, Plana JC et al. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. Am J Cardiol, 2011; 107: 1375–1380
17. Demant EJ. Inactivation of cytochrome c oxidase activity in mitochondrial membranes during redox cycling of doxorubicin. Biochem Pharmacol, 1991; 41: 543–552
18. Palmeira CM, Serrano J, Kuehl DW, Wallace KB. Preferential oxidation of cardiac mitochondrial DNA following acute intoxication with doxorubicin. Biochim Biophys Acta, 1997; 1321: 101–106
19. Mimnaugh EG, Trush MA, Bhatnagar M, Gram TE. Enhancement of reactive oxygen-dependent mitochondrial membrane lipid peroxidation by the anticancer drug adriamycin. Biochem Pharmacol, 1985; 34: 847–856
20. Kang YJ, Chen Y, Yu A, Voss-McCowan M, Epstein PN. Overexpression of metallothionein in the heart of transgenic mice suppresses doxorubicin cardiotoxicity. J Clin Invest, 1997; 100: 1501–1506
21. Pereira OG, Alegria JP, Gouveia AP. Índice Nacional Terapêutico – Edição de Mesa. Tupam Editores, Lisboa, Portugal 2005: 633–856, 1429–1513
22. Suter TM, Ewer MS. Cancer drugs and then heart: Importance and management. Eur Heart J, 2013; 34: 1102–1111
23. Tenero D, Boike S, Boyle D et al. Steady-state pharmacokinetics of carvedilol and its enantiomers in patientswith congestive heart failure. J Clin Pharmacol, 2000; 40: 844–853
24. Packer M, Bristow MR, Cohn JN et al. for the U.S. Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med, 1996; 334: 1349–1355
25. El-Shitany NA, Tolba OA, El-Shanshory MR, El-Hawary EE. Protective effect of carvedilol on adriamycin-induced left ventricular dysfunction in children with acute lymphoblastic leukemia. J Card Fail, 2012; 18: 607–613
26. Jonsson O, Behnam-Motlagh P, Persson M, Henriksson R, Grankvist K. Increase in doxorubicin cytotoxicity by carvedilol inhibition of P-glycoprotein activity. Biochem Pharmacol, 1999; 58: 1801–1806
27. Oliveira PJ, Bjork JA, Santos MS et al. Carvedilol-mediated antioxidant protection against doxorubicin-induced cardiac mitochondrial toxicity. Toxicol Appl Pharmacol, 2004; 200: 159–168
28. Matsui H, Morishima I, Numaguchi Y, Toki Y, Okumura K, Hayakawa T. Protective effects of carvedilol against doxorubicininduced cardiomyopathy in rats. Life Sci, 1999; 65: 1265–1274
29. Jonsson O, Behnam-Motlagh P, Persson M, Henriksson R, Grankvist K. Increase in doxorubicin cytotoxicity by carvedilol inhibition of P-glycoprotein activity. Biochem Pharmacol, 1999; 58: 1801–1806
30. Ganame J, Claus P, Uyttebroeck A et al. Myocardial dysfunction late after low-dose anthracycline treatment in asymptomatic pediatric patients. J Am Soc Echocardiogr, 2007; 20: 1351–1358
31. Ewer MS, Ali MK, Gibbs HR et al. Cardiac diastolic function in pediatric patients receiving doxorubicin. Acta Oncol, 1994; 33: 645–649